Cargando…

Current and future use of neuromodulation in heart failure( )

Autonomic imbalance is a common finding in heart failure (HF) with reduced ejection fraction (HFrEF). Addressing different targets within the autonomic nervous systems has been evaluated in patients with HF, including renal sympathetic denervation, vagal nerve stimulation, and baroreceptor activatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duncker, David, Bauersachs, Johann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Neuromodulation for patients with HFrEF Supplement Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385118/ https://www.ncbi.nlm.nih.gov/pubmed/35991620 http://dx.doi.org/10.1093/eurheartjsupp/suac031

Ejemplares similares

Neuromodulation devices for heart failure( )
por: Dusi, Veronica, et al.
Publicado: (2022)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Sympathetic activation in heart failure( )
por: Gronda, E, et al.
Publicado: (2022)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
por: Voors, Adriaan A., et al.
Publicado: (2020)

The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta‐analysis of COMPANION and CARE‐HF
por: Cleland, John G.F., et al.
Publicado: (2022)

Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
por: McDowell, Kirsty, et al.
Publicado: (2022)

Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
por: Cooper, Trond J., et al.
Publicado: (2022)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Representation matters: a call for inclusivity and equity in heart failure clinical trials
por: Reza, Nosheen, et al.
Publicado: (2022)

The four pillars of HFrEF therapy: is it time to treat heart failure regardless of ejection fraction?
por: Docherty, Kieran F, et al.
Publicado: (2022)

Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe
por: Marx, Nikolaus, et al.
Publicado: (2022)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
por: Gori, Mauro, et al.
Publicado: (2022)

Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis
por: Bilak, Joanna M, et al.
Publicado: (2022)

Dear colleagues: enough with the men-only author panels
por: Van Spall, Harriette G C, et al.
Publicado: (2022)

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Time for change
por: Zieroth, Shelley, et al.
Publicado: (2022)

Getting ahead of the game: in-hospital initiation of HFrEF therapies
por: Biegus, Jan, et al.
Publicado: (2022)

Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come
por: Piña, Ileana L, et al.
Publicado: (2022)

Sacral neuromodulation for female pelvic floor disorders
por: El-Azab, Ahmed S., et al.
Publicado: (2019)

Clinical Evidence and Proposed Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: A Class Effect?
por: Deschaine, Brent, et al.
Publicado: (2022)

Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Fukuta, Hidekatsu
Publicado: (2020)

Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives
por: van Woerden, Gijs, et al.
Publicado: (2022)

What causes exertional dyspnoea in patients with atrial fibrillation? Implications for catheter ablation in patients with heart failure
por: Packer, Milton
Publicado: (2021)

Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)
por: Linde, Cecilia, et al.
Publicado: (2022)

Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS‐HFpEF study
por: Venkateshvaran, Ashwin, et al.
Publicado: (2022)

Epicardial Fat in Heart Failure with Preserved Ejection Fraction: Bad Actor or Just Lying Around?
por: Oduah, Mary-Tiffany, et al.
Publicado: (2023)

Current Approaches to Neuromodulation in Primary Headaches: Focus on Vagal Nerve and Sphenopalatine Ganglion Stimulation
por: Puledda, Francesca, et al.
Publicado: (2016)

Recent Trends in the Use of Electrical Neuromodulation in Parkinson’s Disease
por: Brittain, John-Stuart, et al.
Publicado: (2018)

Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology
por: Guazzi, Marco, et al.
Publicado: (2022)

10-kHz High-Frequency SCS Therapy: A Clinical Summary
por: Russo, Marc, et al.
Publicado: (2015)

Clinical experience with percutaneous tibial nerve stimulation in the elderly; do outcomes differ by gender?
por: Palmer, Cristina, et al.
Publicado: (2019)

The role of urodynamics in females with lower urinary tract symptoms
por: Al Mousa, Riyad T., et al.
Publicado: (2019)

Neuromuscular Electrical Stimulation Reduces Leg Cramps in Patients With Lumbar Degenerative Disorders: A Randomized Placebo‐Controlled Trial
por: Harmsen, Jan‐Frieder, et al.
Publicado: (2020)

Safety of Bilateral Staged Magnetic Resonance‐Guided Focused Ultrasound Thalamotomy for Essential Tremor
por: Scantlebury, Nadia, et al.
Publicado: (2023)

Update of Neuromodulation in Chronic Migraine
por: Yuan, Hsiangkuo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f4k3spqb1rhfojgke7nihrrlab